|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Efficacy of mosapride citrate with polyethylene glycol solution for colonoscopy preparation显示文摘AIM:To evaluate the efficacy and safety of adjunctive mosapride citrate for bowel preparation before colonoscopy. METHODS:We conducted a randomized,double-blind, placebo-controlled study with mosapride in addition to polyethylene glycol(PEG)-electrolyte solution.Of 250 patients undergoing colonoscopy,124 were randomized to receive 2 L PEG plus 15 mg of mosapride citrate (mosapride group),and 126 received 2 L PEG plus placebo(placebo group).Patients completed a questionnaire reporting the acceptability and tolerability of the bowel preparation process.The efficacy of bowel preparation was assessed by colonoscopists using a 5-point scale based on Aronchick's criteria.The primary end point was optimal bowel preparation rates(scores of excellent/good/fair vs poor/inadequate). RESULTS:A total of 249 patients were included in the analysis.In the mosapride group,optimal bowel preparation rates were significantly higher in the left colon compared with the placebo group(78.2%vs 65.6%,P<0.05),but not in the right colon(76.5%vs 66.4%,P=0.08).After excluding patients with severe constipation,there was a significant difference in bowel preparation in both the left and right colon(82.4%vs 66.7%,80.8%vs 67.5%,P<0.05,P<0.01).The incidence of adverse events was similar in both groups. Among the subgroup who had previous colonoscopy experience,a significantly higher number of patients in the mosapride group felt that the current preparation was easier compared with patients in the placebo group(34/72 patients vs 24/74 patients,P<0.05). CONCLUSION:Mosapride citrate may be an effective and safe adjunct to PEG-electrolyte solution that leads to improved quality of bowel preparation,especially in patients without severe constipation. | Masahiro Tajika Yasumasa Niwa Vikram Bhatia Hiroki Kawai Shinya Kondo Akira Sawaki Nobumasa Mizuno Kazuo Hara Susumu Hijioka Kazuya Matsumoto Yuji Kobayashi Akira Saeki Asana Akabane Koji Komori Kenji Yamao | 2012 | World Journal of Gastroenterology2012，18，20： | 21 |
| 2 | Treatment strategies for advanced hepatocellular carcinoma:Sorafenib vs hepatic arterial infusion chemotherapy显示文摘Sorafenib is used worldwide as a first-line standardsystemic agent for advanced hepatocellular carcinoma(HCC) on the basis of the results of two large-scale Phase Ⅲ trials. Conversely,hepatic arterial infusion chemotherapy(HAIC) is one of the most recommended treatments in Japan. Although there have been no randomized controlled trials comparing sorafenib with HAIC,several retrospective analyses have shown no significant differences in survival between the two therapies. Outcomes are favorable for HCC patients exhibiting macroscopic vascular invasion when treated with HAIC rather than sorafenib,whereas in HCC patients exhibiting extrahepatic spread or resistance to transcatheter arterial chemoembolization,good outcomes are achieved by treatment with sorafenib rather than HAIC. Additionally,sorafenib is generally used to treat patients with Child-Pugh A,while HAIC is indicated for those with either Child-Pugh A or B. Based on these findings,we reviewed treatment strategies for advanced HCC. We propose that sorafenib might be used as a first-line treatment for advanced HCC patients without macroscopic vascular invasion or Child-Pugh A,while HAIC is recommended for those with macroscopic vascular invasion or Child-Pugh A or B. Additional research is required to determine the best second-line treatment for HAIC non-responders with Child-Pugh B through future clinical trials. | Issei Saeki Takahiro Yamasaki Masaki Maeda Takuro Hisanaga Takuya Iwamoto Koichi Fujisawa Toshihiko Matsumoto Isao Hidaka Yoshio Marumoto Tsuyoshi Ishikawa Naoki Yamamoto Yutaka Suehiro Taro Takami Isao Sakaida | 2018 | World Journal of Hepatology2018，10，9： | 10 |
| 3 | IgM反应是熊去氧胆酸和苯扎贝特治疗原发性胆汁性胆管炎的预后生物标志物显示文摘【据《J Gastroenterol Hepatol》2019年11月报道】题:IgM反应是熊去氧胆酸和苯扎贝特治疗原发性胆汁性胆管炎的预后生物标志物(作者Takano K等)原发性胆汁性胆管炎(PBC)患者对熊去氧胆酸(UDCA)不敏感,有可能发展为肝硬化和肝衰竭。苯扎贝特可作为这些患者的二线药物选择。该研究旨在评价UDCA联合苯扎贝特治疗UDCA难治性PBC的远期疗效,并探讨影响预后的因素。 | 李艳艳 高润平 TAKANO K SAEKI C OIKAWA T | 2020 | 临床肝胆病杂志2020，36，3： | 8 |
| 4 | Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011显示文摘 | Hisanori Umehara Kazuichi Okazaki Yasufumi Masaki Mitsuhiro Kawano Motohisa Yamamoto Takako Saeki Shoko Matsui Tadashi Yoshino Shigeo Nakamura Shigeyuki Kawa Hideaki Hamano Terumi Kamisawa Toru Shimosegawa Akira Shimatsu Seiji Nakamura Tetsuhide Ito Kenji | 2012 | Modern Rheumatology2012，，1： | 4 |
| 5 | Identification of Naturally Occurring Polyamines as Root-Knot Nematode Attractants显示文摘Root-knot nematodes(RKNs;genus Meloidogyne)are a class of plant parasites that infect the roots of many plant species.It is believed that RKNs target certain signaling molecules derived from plants to locate their hosts;however,currently,no plant compound has been unambiguously identified as a universal RKN attractant.To address this question,we screened a chemical library of synthetic compounds for Meloidogyne incognita attractants.The breakdown product of aminopropylam ino-anthraquinone,1,3-diam inopropane,as well as its related compounds,putrescine and cadaverine,were found to attract M.incognita.After exam ining various polyamines,M.incognita were found to be attracted specifically by natural com pounds that possess three to five methylene groups between two terminal amino groups.Using cryo-TO F-SIM S/SEM,cadaverine was indeed detected in soybean root cortex cells and the surrounding rhizosphere,establishing a chemical gradient.In addition to cadaverine,putrescine and 1,3-diam inopropane were also detected in root exudate by HPLC-MS/MS.Furtherm ore,exogenously applied cadaverine is sufficient to enhance M.incognita infection of Arabidopsis seedlings.These results suggest that M.incognita is likely attracted by polyam ines to locate the appropriate host plants,and the naturally occurring polyamines have potential applications in agriculture in developing protection strategies for crops from RKN infection. | Morihiro Oota Allen Yi-Lun Tsai Dan Aoki Yasuyuki Matsushita Syuuto Toyoda Kazuhiko Fukushima Kentaro Saeki Kei Toda Laetitia Perfus-Barbeoch Bruno Favery Hayato Ishikawa Shinichiro Sawa | 2020 | Molecular Plant2020，13，4： | 4 |
| 6 | Supportive therapies for prevention of hepatocellular carcinoma recurrence and preservation of liver function显示文摘Hepatocellular carcinoma(HCC) is one of the deadliest cancers in the world and is associated with a high risk of recurrence. The development of a wide range of new therapies is therefore essential. In this study, from the perspective of supportive therapy for the prevention of HCC recurrence and preservation of liver function in HCC patients, we surveyed a variety of different therapeutic agents. We show that branched chain amino acids(BCAA) supplementation and late evening snack with BCAA, strategies that address issues of protein-energy malnutrition, are important for liver cirrhotic patients with HCC. For chemoprevention of HCC recurrence, we show that viral control after radical treatment is important. We also reviewed the therapeutic potential of antiviral drugs, sorafenib, peretinoin, iron chelators. Sorafenib is a kinase inhibitor and a standard therapy in the treatment of advanced HCC. Peretinoin is a vitamin A-like molecule that targets the retinoid nuclear receptor to induce apoptosis and inhibit tumor growth in HCC cells. Iron chelators, such as deferoxamine and deferasirox, act to prevent cancer cell growth. These chelators may have potential as combination therapies in conjunction with peretinoin. Finally, we review the potential inhibitory effect of bone marrow cells on hepatocarcinogenesis. | Taro Takami Takahiro Yamasaki Issei Saeki Toshihiko Matsumoto Yutaka Suehiro Isao Sakaida | 2016 | World Journal of Gastroenterology2016，22，32： | 4 |
| 7 | Crystal Structures of Human Dipeptidyl Peptidase Ⅳ in its Apo and Diprotin B-complexed Forms显示文摘Dipeptidyl 肽酶 IV (DPPIV ) 丝氨酸朊酶 oligopeptidasefamily 属于 prolyl,被知道把许多规章的生物功能和过时的人或物显示在类型 2 糖尿病被含有。开发选择 humanDPPIV (hDPPIV ) 禁止者因此是重要的。在这研究,我们在 1.9A 分辨率决定了 apo hDPPIV 的水晶结构。我们 apo hDPPIV 的高分辨率的水晶结构在活性部位揭示了钠离子和甘油分子的存在。以便阐明 hDPPIV 绑定模式和底层特性,我们在 2.1 一分辨率决定了 hDPPIV-diprotin B (Val-Pro-Leu ) 建筑群的水晶结构,并且在在 diprotin B anddiprotin A (Ile-Pro-Ile ) 之间的有约束力的模式澄清了差别进 hDPPIV 的活性部位。在我们的水晶结构和报导 apo hDPPIV 结构之间的比较表明那断然为功能的组充电了并且保存了贡献的水分子有 hDPPIV 的 ligands 的相互作用。这些结果为有势力 hDPPIV 禁止者的设计是有用的。 | Hajime H1RAMATSU Kiyoshi KYONO Atsushi YAMAMOTO Kazuhiko SAEKI Hideaki SHIMA Shigeru SUGIYAMA Koji INAKA Ryo SHIMIZU | 2007 | Acta Biochimica et Biophysica Sinica2007，39，5： | 4 |
| 8 | A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details显示文摘 | Hisanori Umehara Kazuichi Okazaki Yasufumi Masaki Mitsuhiro Kawano Motohisa Yamamoto Takako Saeki Shoko Matsui Takayuki Sumida Tsuneyo Mimori Yoshiya Tanaka Kazuo Tsubota Tadashi Yoshino Shigeyuki Kawa Ritsuro Suzuki Tsutomu Takegami Naohisa Tomosugi Nozo | 2012 | Modern Rheumatology2012，，1： | 4 |
| 9 | Genetic factors related to gastric cancer susceptibility identified using a genome‐wide association study显示文摘 | Norihisa Saeki Hiroe Ono Hiromi Sakamoto Teruhiko Yoshida | 2012 | Cancer Sci2012，，1： | 3 |
| 10 | Clinical usefulness of ursodeoxycholic acid for Japanese patients with autoimmune hepatitis显示文摘AIM To evaluate the therapeutic effects of ursodeoxycholic acid(UDCA) on autoimmune hepatitis(AIH).METHODS A total 136 patients who were diagnosed with AIH were included in our study. All of the patients underwent a liver biopsy, and had at least a probable diagnosis on the basis of either the revised scoring system or the simplified scores. Initial treatment included UDCA monotherapy(Group U, n = 48) and prednisolone(PSL) monotherapy(Group P, n = 88). Group U was further classified into two subgroups according to the effect of UDCA: Patients who had achieved remission induction with UDCA monotherapy and showed no sign of relapse(Subgroup U1, n = 34) and patients who additionally received PSL during follow-up(Subgroup U2, n = 14). We compared the clinical and histological findings between each groups, and investigated factorscontributing to the response to UDCA monotherapy.RESULTS In Group U, 34 patients(71%) achieved and maintained remission over 49(range: 8-90) mo(Subgroup U1) and 14 patients(29%) additionally received PSL(Subgroup U2) during follow-up. Two patients in Subgroup U2 achieved remission induction once but additionally required PSL administration because of relapse(15 and 35 mo after the start of treatment). The remaining 12 patients in Subgroup U2 failed to achieve remission induction during follow-up, and PSL was added during 7(range: 2-18) mo. Compared with Subgroup U2, Subgroup U1 had significantly lower alanine aminotransferase(ALT) levels at onset(124 IU/L vs 262 IU/L, P = 0.023) and a significantly higher proportion of patients with mild inflammation(A1) on histological examination(70.6% vs 35.7%, P = 0.025). When multivariate analysis was performed to identify factors contributing to the response to UDCA monotherapy, only a serum ALT level of 200 IU/L or lower was found to be associated with a significant difference(P = 0.013).CONCLUSION To prevent adverse events related to corticosteroids, UDCA monotherapy for AIH needs to be considered in patients with a serum ALT level of 200 IU/L or lower. | Yuichi Torisu Masanori Nakano Keiko Takano Ryo Nakagawa Chisato Saeki Atsushi Hokari Tomohisa Ishikawa Masayuki Saruta Mikio Zeniya | 2017 | World Journal of Hepatology2017，9，1： | 3 |
| 11 | Effects of denosumab treatment in chronic liver disease patients with osteoporosis显示文摘BACKGROUND Effective treatment of osteoporosis is essential for improving morbidity and health-related quality of life in chronic liver disease(CLD)patients.Denosumab has been shown to increase bone mineral density(BMD)and decrease the risk of osteoporotic fracture in the general population.However,there are few reports evaluating the efficacy of denosumab in CLD patients.AIM To investigated the effects and safety of denosumab in CLD patients with osteoporosis.METHODS Sixty CLD patients with osteoporosis were subcutaneously administered denosumab once every 6 mo.The study period for evaluating efficacy and safety was 12 mo.Changes from baseline in BMD at the lumbar spine,femoral neck,and total hip were evaluated at 12 mo of denosumab treatment.Bone turnover and quality were assessed by measuring serum tartrate-resistant acid phosphatase-5b(bone resorption marker),serum total procollagen type I N-terminal propeptide(bone formation maker),and plasma pentosidine(bone quality marker).RESULTS Among the 405 CLD patients,138(34.1%)patients were diagnosed with osteoporosis;among these,78 patients met the exclusion criteria and thus 60 patients were finally included in the present study.The median percentage changes from baseline to 12 mo of denosumab treatment in BMD at the lumbar spine,femoral neck,and total hip were+4.44%,+3.71%,and+4.03%,respectively.Denosumab significantly improved BMD,regardless of sex,patient age,and presence of liver cirrhosis.Serum tartrate-resistant acid phosphatase-5b and procollagen type I N-terminal propeptide levels constantly and significantly declined after denosumab treatment(P<0.001).Plasma pentosidine levels were also significantly lower at 12 mo of treatment(P=0.010).No patients experienced fractures and moderate-to-severe adverse events,except for transient hypocalcemia.CONCLUSION Denosumab treatment was safe and increased BMD,suppressed bone turnover,and improved bone quality marker levels in CLD patients with osteoporosis,irrespective of differences in baseline characteristics. | Chisato Saeki Mitsuru Saito Tsunekazu Oikawa Masanori Nakano Yuichi Torisu Masayuki Saruta Akihito Tsubota | 2020 | World Journal of Gastroenterology2020，26，33： | 3 |
| 12 | Aberrant Eph B/ephrin-B expression in experimental gastric lesions and tumor cells显示文摘AIM: To determine whether the expression profiles of Eph B receptor and ephrin-B ligand can be used as markers for dysplastic/oncogenic transformation in gastric mucosa.METHODS: The protein expression and localization ofEph B and ephrin-B in normal, ulcerated regenerating, and dysplastic gastric mucosa were examined in a rat experimental model by immunolabeling, and m RNA expression was assessed in four human gastric carcinoma cell lines by reverse transcription-polymerase chain reaction.RESULTS: Ephrin-B- and Eph B-expressing regions were divided along the pit-gland axis in normal gastric units. Eph B2 was transiently upregulated in the experimental ulcer, and its expression domain extended to gastric pits and/or the luminal surface where ephrin-B-expressing pit cells reside. Eph B2, B3, and B4 and ephrin-B1 were coexpressed in the experimental gastric dysplasia, and more than one ligand-receptor pair was highly expressed in each of the gastric carcinoma cell lines.CONCLUSION: Robust and stable coexpression of Eph B and ephrin-B is a feature common to experimentally induced gastric dysplasia and human gastric carcinoma cell lines as compared to normal gastric and ulcerated regenerating epithelia. Thus, Eph B/ephrin-B may be a useful marker combination for dysplastic/oncogenic transformation in gastric cancer. | Shintaro Uchiyama Noritaka Saeki Kazushige Ogawa | 2015 | World Journal of Gastroenterology2015，21，2： | 3 |
| 13 | Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma显示文摘AIM To evaluate the inhibitory effects of deferasirox(DFX) against hepatocellular carcinoma(HCC) through basic and clinical studies.METHODS In the basic study, the effect of DFX was investigated in three hepatoma cell lines(Hep G2, Hep3 B, and Huh7), as well as in an N-nitrosodiethylamine-induced murine HCC model. In the clinical study, six advanced HCC patients refractory to chemotherapy were enrolled. The initial dose of DFX was 10 mg/kg per day and was increased by 10 mg/kg per day every week, until the maximum dose of 30 mg/kg per day. The duration of a single course of DFX therapy was 28 consecutive days. In the event of dose-limiting toxicity(according to the Common Terminology Criteria for Adverse Events v.4.0), DFX dose was reduced.RESULTS Administration of DFX inhibited the proliferation of hepatoma cell lines and induced the activation of caspase-3 in a dose-dependent manner in vitro. In the murine model, DFX treatment significantly suppressed the development of liver tumors(P < 0.01), and significantly upregulated the mR NA expression levels of hepcidin(P < 0.05), transferrin receptor 1(P < 0.05), and hypoxia inducible factor-1α(P < 0.05) in both tumor and non-tumor tissues, compared with control mice. In the clinical study, anorexia and elevated serum creatinine were observed in four and all six patients, respectively. However, reduction in DFX dose led to decrease in serum creatinine levels in all patients. After the first course of DFX, one patient discontinued the therapy. We assessed the tumor response in the remaining five patients; one patient exhibited stable disease, while four patients exhibited progressive disease. The one-year survival rate of the six patients was 17%.CONCLUSION We demonstrated that DFX inhibited HCC in the basic study, but not in the clinical study due to dose-limiting toxicities. | Issei Saeki Naoki Yamamoto Takahiro Yamasaki Taro Takami Masaki Maeda Koichi Fujisawa Takuya Iwamoto Toshihiko Matsumoto Isao Hidaka Tsuyoshi Ishikawa Koichi Uchida Kenji Tani Isao Sakaida | 2016 | World Journal of Gastroenterology2016，22，40： | 3 |
| 14 | A ruptured large extraluminal ileal gastrointestinal stromal tumor causing hemoperitoneum显示文摘We describe an 87-year-old woman with a large ileal gastrointestinal stromal tumor (GIST) causing hemoperitoneum. A CT scan demonstrated a large heterogeneous mass measuring about 13 cm × 11 cm in the pelvis and hemoperitoneum, with a non-uniform enhancement pattern. The mass was diagnosed as a GIST originating from the gastrointestinal tract. She underwent an urgent laparotomy and an ileal GIST with a rupture was found 130 cm from the anal to the Treitz’s ligament. Hemoperitoneum caused by ileal GIST rupture is a rare condition. Bleeding in the large tumor leading to rupture of the capsule might cause hemoperitoneum in the present case. | Shoji Hirasaki Kohei Fujita Minoru Matsubara Hiromitsu Kanzaki Hiromichi Yamane Masato Okuda Seiyuu Suzuki Atsuko Shirakawa Hideyuki Saeki | 2008 | World Journal of Gastroenterology2008，14，18： | 3 |
| 15 | Development and application of traffic accident density estimation models using kernel density estimation显示文摘Traffic accident frequency has been decreasing in Japan in recent years.Nevertheless,many accidents still occur on residential roads.Area-wide traffic calming measures including Zone 30,which discourages traffic by setting a speed limit of 30 km/h in residential areas,have been implemented.However,no objective implementation method has been established.Development of a model for traffic accident density estimation explained by GIS data can enable the determination of dangerous areas objectively and easily,indicating where area-wide traffic calming can be implemented preferentially.This study examined the relations between traffic accidents and city characteristics,such as population,road factors,and spatial factors.A model was developed to estimate traffic accident density.Kernel density estimation(KDE) techniques were used to assess the relations efficiently.Besides,16 models were developed by combining accident locations,accident types,and data types.By using them,the applicability of traffic accident density estimation models was examined.Results obtained using Spearman rank correlation show high coefficients between the predicted number and the actual number.The model can indicate the relative accident risk in cities.Results of this study can be used for objective determination of areas where area-wide traffic calming can be implemented preferentially,even if sufficient traffic accident data are not available. | Seiji Hashimoto Syuji Yoshiki Ryoko Saeki Yasuhiro Mimura Ryosuke Ando Shutaro Nanba | 2016 | Journal of Traffic and Transportation Engineering(English Edition)2016，3，3： | 3 |
| 16 | Human pluripotent stem cells:Towards therapeutic development for the treatment of lifestyle diseases显示文摘There are two types of human pluripotent stem cells: Embryonic stem cells(ESCs) and induced pluripotent stem cells(iPSCs),both of which launched themselves on clinical trials after having taken measures to overcome problems: Blocking rejections by immunosuppressants regarding ESCs and minimizing the risk of tumorigenicity by depleting exogenous gene components regarding iP SCs.It is generally assumed that clinical applications of human pluripotent stem cells should be limited to those cases where there are no alternative measures for treatments because of the risk in transplanting those cells to living bodies.Regarding lifestyle diseases,we have already several therapeutic options,and thus,development of human pluripotent stem cell-based therapeutics tends to be avoided.Nevertheless,human pluripotent stem cells can contribute to the development of new therapeutics in this field.As we will show,there is a case where only a short-term presence of human pluripotent stem-derived cells can exert long-term therapeutic effects even after they are rejected.In those cases,immunologically rejections of ESC-or allogenic iP SC-derived cells may produce beneficial outcomes by nullifying the risk of tumorigenesis without deterioration of therapeutic effects.Another utility of human pluripotent stem cells is the provision of an innovative tool for drug discovery that are otherwise unavailable.For example,clinical specimens of human classical brown adipocytes(BAs),which has been attracting a great deal of attention as a new target of drug discovery for the treatment of metabolic disorders,are unobtainable from living individuals due to scarcity,fragility and ethical problems.However,BA can easily be produced from human pluripotent stem cells.In this review,we will contemplate potential contribution of human pluripotent stem cells to therapeutic development for lifestyle diseases. | Miwako Nishio Masako Nakahara Akira Yuo Kumiko Saeki | 2016 | World Journal of Stem Cells2016，8，2： | 2 |
| 17 | Clinical significance of vascular endothelial growth factor‐C (VEGF‐C) in breast cancer显示文摘 | Junko Kinoshita Kaoru Kitamura Akira Kabashima Hiroshi Saeki Shinji Tanaka Keizo Sugimachi | 2001 | Breast Cancer Research and Treatment2001，，2： | 2 |
| 18 | Prognostic relevance of KRAS and BRAF mutations in Japanese patients with colorectal cancer显示文摘 | Ryota Nakanishi Jun Harada Munkhbold Tuul Yan Zhao Koji Ando Hiroshi Saeki Eiji Oki Takefumi Ohga Hiroyuki Kitao Yoshihiro Kakeji Yoshihiko Maehara | 2013 | International Journal of Clinical Oncology2013，，6： | 2 |
| 19 | Mouse models for investigating the underlying mechanisms of nonalcoholic steatohepatitis-derived hepatocellular carcinoma显示文摘As the incidence of hepatocellular carcinoma(HCC) caused by infection with the hepatotropic viruses hepatitis B and hepatitis C decreases, greater attention has become focused on HCC caused by nonalcoholic steatohepatitis(NASH), an advanced form of nonalcoholic fatty liver disease which has shown increasing prevalence in correspondence with the overall increase in metabolic syndrome over the recent decades. Several clinical population studies have shown a positive relationship between NASH and HCC, while also providing initial insights into the underlying mechanisms of HCC development from NASH. Research into the pathological progression of NASH to HCC has advanced by use of several beneficial rodent models. In this review, we summarize the established mouse models for preclinical research of NASH-associated HCC and discuss the underlying hepatic mechanisms of NASH-related tumorigenesis identified to date that could lead to new targets for treatment and prevention. | Kazuki Takakura Tsunekazu Oikawa Yoichi Tomita Yusuke Mizuno Masanori Nakano Chisato Saeki Yuichi Torisu Masayuki Saruta | 2018 | World Journal of Gastroenterology2018，24，18： | 2 |
| 20 | 用背景音乐促进课堂教学显示文摘在研究生时代,当我第一次听说在英语课上使用背景音乐(BGM)时,我觉得“那简直是发疯”。但我却敢于在我任教的中学英语课上加以尝试。六月的一天,我冒险第一次用 BGM 开始英语课。学生们很吃惊,向我投来奇怪、怀疑的目光,班上甚至还爆发出一阵哄笑。然而,我继续在不同的场合放BGM——在两人对话练习中或课堂讨论期间。现在我的学生说他们喜欢在背景音乐中学习英语。他们为我提供 BGM 的反馈信息,建议我放何种音乐以及何时放音乐。这里我想谈一下我从用 BGM | Kenji Saeki 于泉 | 1994 | 外语教学理论与实践1994，，4： | 2 |
您所在的机构暂未开通此部分的功能，请联系管理员